ERBB2 and non-small cell lung carcinoma: Because of comprehensive genomic profiling, other genetic aberrances in NSCLC, such as mutations in Kirsten rat sarcoma (KRAS), amplification of human epidermal growth factor receptor‐2 (HER2), and other genotypes of the driver genes, have been thought highly targetable and investigated in preclinical and clinical trials.9